Open AccessAustralian Gonococcal Surveillance Programme 1 January to 31 March 2020
Author(s) -
Monica M Lahra,
Masoud Shoushtari,
Tiffany R Hogan
Publication year - 2020
Publication title -
communicable diseases intelligence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.616
H-Index - 6
ISSN - 2209-6051
DOI - 10.33321/cdi.2020.44.61
Subject(s) - azithromycin , medicine , ceftriaxone , neisseria gonorrhoeae , penicillin , ciprofloxacin , regimen , gonorrhea , antibiotics , antibiotic resistance , family medicine , microbiology and biotechnology , human immunodeficiency virus (hiv) , biology
The National Neisseria Network (NNN), Australia, comprises reference laboratories in each state and territory that report data on susceptibility profiles for clinical Neisseria gonorrhoeae isolates from each jurisdiction for an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The antibiotics (ceftriaxone, azithromycin, ciprofloxacin, and penicillin) represent current or potential agents used for the treatment of gonorrhoea. Ceftriaxone, combined with azithromycin, is the recommended treatment regimen for gonorrhoea in the majority of Australia. However, there are substantial geographic differences in susceptibility patterns in Australia, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid, and azithromycin is recommended for the treatment of gonorrhoea. Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.